Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 4 years, with Sep 2025 value amounting to $56.5 million.

  • Ascendis Pharma A's Other Non-Current Liabilities rose 21.71% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year increase of 21.71%. This contributed to the annual value of $73.6 million for FY2024, which is 66.02% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Other Non-Current Liabilities stood at $56.5 million, which was up 24.93% from $45.2 million recorded in Q2 2025.
  • Ascendis Pharma A's Other Non-Current Liabilities' 5-year high stood at $72.6 million during Q4 2024, with a 5-year trough of $14.1 million in Q1 2022.
  • Its 3-year average for Other Non-Current Liabilities is $39.7 million, with a median of $40.0 million in 2025.
  • Data for Ascendis Pharma A's Other Non-Current Liabilities shows a peak YoY surged of 63.91% (in 2024) over the last 5 years.
  • Over the past 4 years, Ascendis Pharma A's Other Non-Current Liabilities (Quarterly) stood at $32.6 million in 2022, then spiked by 35.75% to $44.3 million in 2023, then soared by 63.91% to $72.6 million in 2024, then rose by 21.71% to $56.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $56.5 million for Q3 2025, versus $45.2 million for Q2 2025 and $40.0 million for Q1 2025.